Guardant Health (GH) Stock Forecast & Price Target

$31.67 +0.54 (+1.73%)

(As of 12/20/2024 05:16 PM ET)

Guardant Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 15 Analyst Ratings

Sell
0

Hold
0

Buy
15

Based on 15 Wall Street analysts who have issued ratings for Guardant Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 15 have given a buy rating for GH.

Consensus Price Target

$40.60
28.20% Upside

According to the 15 analysts' twelve-month price targets for Guardant Health, the average price target is $40.60. The highest price target for GH is $50.00, while the lowest price target for GH is $32.00. The average price target represents a forecasted upside of 28.20% from the current price of $31.67.

Get the Latest News and Ratings for GH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Guardant Health and its competitors.

GH Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	15 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)
Hold	0 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$40.60	$40.60	$39.31	$47.71
Forecasted Upside	28.20% Upside	24.35% Upside	67.36% Upside	65.96% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

GH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Guardant Health Stock vs. The Competition

Type	Guardant Health	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	28.20% Upside	25,828.59% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent GH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$48.00 ➝ $50.00	+73.91%
11/7/2024	The Goldman Sachs Group 2 of 5 stars		Boost Target	Buy ➝ Buy	$32.00 ➝ $36.00	+24.35%
10/30/2024	Sanford C. Bernstein 3 of 5 stars		Lower Target	Outperform ➝ Outperform	$40.00 ➝ $35.00	+49.51%
10/17/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$60.00 ➝ $50.00	+131.27%
8/21/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$32.00 ➝ $40.00	+42.30%
8/13/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$30.00 ➝ $34.00	+11.73%
Get the Latest News and Ratings for GH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$40.00 ➝ $45.00	+48.27%
8/8/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$41.00 ➝ $42.00	+38.61%
8/8/2024	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $37.00	+21.79%
7/30/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$45.00 ➝ $50.00	+37.51%
7/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $40.00	+22.89%
6/28/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$36.00	+23.92%
6/4/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$30.00 ➝ $38.00	+38.13%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$32.00	+17.09%
5/24/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$44.00 ➝ $44.00	+79.01%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
11/13/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$27.00	+25.12%
11/8/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$55.00 ➝ $50.00	+111.24%
9/8/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$60.00 ➝ $55.00	+129.26%
2/24/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$70.00 ➝ $53.00	+104.95%
1/4/2023	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Outperform	$36.00	+34.83%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:00 AM ET.

GH Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Guardant Health is $40.60, with a high forecast of $50.00 and a low forecast of $32.00.
: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GH shares.
: According to analysts, Guardant Health's stock has a predicted upside of 28.20% based on their 12-month stock forecasts.
: Guardant Health has been rated by research analysts at JPMorgan Chase & Co., Leerink Partners, Sanford C. Bernstein, and The Goldman Sachs Group in the past 90 days.
: Analysts like Guardant Health more than other "medical" companies. The consensus rating for Guardant Health is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

⭕ [URGENT] Buy Alert just triggered (Ad)

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

This page (NASDAQ:GH) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Guardant Health (GH) Stock Forecast & Price Target